Inflammation and erythropoietin hyporesponsiveness - Role of pentoxifylline - An anti TNF-α agent

Nitya Nand, Virender Chauhan, Shashi Seth, Savio Dsouza

Research output: Contribution to journalArticle

Abstract

Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance hemodialysis (MHD). This study was planned to investigate how anemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other and whether Pentoxifylline (PTF) has any role in improving anemia in these subset of patients. Methods: 20 adult patients of end stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance hemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of Pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on hemoglobin, hematocrit and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on hemoglobin and hematocrit after 2 months of rHuePo therapy ('p'>0.05), associated with insignificant decrease in hsCRP, TNF-á and ESR, respectively over 2 months but when Pentoxifylline was added to erythropoietin, the rise in hemoglobin and hematocrit was highly significant ('p'<0.01) which was associated with highly significant decrease in hsCRP, TNF-αand ESR, respectively after completion of the study ('p'<0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

Original languageEnglish
Pages (from-to)190-193
Number of pages4
JournalJournal International Medical Sciences Academy
Volume28
Issue number4
Publication statusPublished - 01-10-2015

Fingerprint

Pentoxifylline
Erythropoietin
Tumor Necrosis Factor-alpha
Inflammation
Blood Sedimentation
Hematocrit
C-Reactive Protein
Hematinics
Renal Dialysis
Anemia
Hemoglobins
Maintenance
Chronic Renal Insufficiency
Chronic Kidney Failure
Ferritins
Serum Albumin
Dialysis
Biomarkers
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{adc3fe2ae5834c06a9fe1178e1cb993d,
title = "Inflammation and erythropoietin hyporesponsiveness - Role of pentoxifylline - An anti TNF-α agent",
abstract = "Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance hemodialysis (MHD). This study was planned to investigate how anemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other and whether Pentoxifylline (PTF) has any role in improving anemia in these subset of patients. Methods: 20 adult patients of end stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance hemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of Pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on hemoglobin, hematocrit and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on hemoglobin and hematocrit after 2 months of rHuePo therapy ('p'>0.05), associated with insignificant decrease in hsCRP, TNF-{\'a} and ESR, respectively over 2 months but when Pentoxifylline was added to erythropoietin, the rise in hemoglobin and hematocrit was highly significant ('p'<0.01) which was associated with highly significant decrease in hsCRP, TNF-αand ESR, respectively after completion of the study ('p'<0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.",
author = "Nitya Nand and Virender Chauhan and Shashi Seth and Savio Dsouza",
year = "2015",
month = "10",
day = "1",
language = "English",
volume = "28",
pages = "190--193",
journal = "Journal International Medical Sciences Academy",
issn = "0971-071X",
publisher = "International Medical Sciences Academy",
number = "4",

}

Inflammation and erythropoietin hyporesponsiveness - Role of pentoxifylline - An anti TNF-α agent. / Nand, Nitya; Chauhan, Virender; Seth, Shashi; Dsouza, Savio.

In: Journal International Medical Sciences Academy, Vol. 28, No. 4, 01.10.2015, p. 190-193.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inflammation and erythropoietin hyporesponsiveness - Role of pentoxifylline - An anti TNF-α agent

AU - Nand, Nitya

AU - Chauhan, Virender

AU - Seth, Shashi

AU - Dsouza, Savio

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance hemodialysis (MHD). This study was planned to investigate how anemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other and whether Pentoxifylline (PTF) has any role in improving anemia in these subset of patients. Methods: 20 adult patients of end stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance hemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of Pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on hemoglobin, hematocrit and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on hemoglobin and hematocrit after 2 months of rHuePo therapy ('p'>0.05), associated with insignificant decrease in hsCRP, TNF-á and ESR, respectively over 2 months but when Pentoxifylline was added to erythropoietin, the rise in hemoglobin and hematocrit was highly significant ('p'<0.01) which was associated with highly significant decrease in hsCRP, TNF-αand ESR, respectively after completion of the study ('p'<0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

AB - Introduction: Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation present in patients of chronic kidney disease (CKD) on maintenance hemodialysis (MHD). This study was planned to investigate how anemia, ESA resistance and the plasma levels of biological markers of inflammation are interlinked to each other and whether Pentoxifylline (PTF) has any role in improving anemia in these subset of patients. Methods: 20 adult patients of end stage renal disease (ESRD) with erythropoietin hyporesponsiveness undergoing twice weekly maintenance hemodialysis were administered subcutaneously 6,000 IU of recombinant human erythropoietin (rHuEPo) twice weekly following dialysis for two months followed by addition of Pentoxifylline to erythropoietin for next four months to complete the study period of six months. The effect of erythropoietin and pentoxifylline on hemoglobin, hematocrit and inflammatory markers that included high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), erythrocyte sedimentation rate (ESR), serum albumin and serum ferritin were studied. Results: There was a insignificant response of erythropoietin alone on hemoglobin and hematocrit after 2 months of rHuePo therapy ('p'>0.05), associated with insignificant decrease in hsCRP, TNF-á and ESR, respectively over 2 months but when Pentoxifylline was added to erythropoietin, the rise in hemoglobin and hematocrit was highly significant ('p'<0.01) which was associated with highly significant decrease in hsCRP, TNF-αand ESR, respectively after completion of the study ('p'<0.01). Conclusion: Pentoxifylline has significant effect in reducing the inflammatory parameters in CKD patients on MHD and therefore is a promising agent in improving anemia in patients of ESRD showing erythropoietin hyporesponsiveness, attributable to inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84962223241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962223241&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 190

EP - 193

JO - Journal International Medical Sciences Academy

JF - Journal International Medical Sciences Academy

SN - 0971-071X

IS - 4

ER -